Use of acetaminophen and risk of endometrial cancer: Evidence from observational studies

Oncotarget

Volumn 8, Issue 21, 2017, Pages 34643-34651

  Ding, Yuan Yuan ^a   Yao, Peng ^a   Verma, Surya ^a   Han, Zhen Kai ^a   Hong, Tao ^a   Zhu, Yong Qiang ^a   Li, Hong Xi ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Acetaminophen; Endometrial cancer; Meta analysis; Observational study; Systematic review

Indexed keywords

PARACETAMOL;

ARTICLE; CANCER RISK; COMPARATIVE STUDY; DISEASE ASSOCIATION; DRUG USE; ENDOMETRIUM CANCER; HUMAN; LONG TERM EXPOSURE; OBSERVATIONAL STUDY; RISK FACTOR; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; CASE CONTROL STUDY; ENDOMETRIUM TUMOR; FACTUAL DATABASE; FEMALE; META ANALYSIS; PROSPECTIVE STUDY;

ACETAMINOPHEN; CASE-CONTROL STUDIES; DATABASES, FACTUAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; OBSERVATIONAL STUDIES AS TOPIC; PROSPECTIVE STUDIES;

EID: 85019929824     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.16663     Document Type: Article

References (44)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87-108
2. Dossus L, Allen N, Kaaks R, Bakken K, Lund E, Tjonneland A, Olsen A, Overvad K, Clavel-Chapelon F, Fournier A, Chabbert-Buffet N, Boeing H, Schutze M, et al. Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2010; 127: 442-451
3. Purdie DM, Green AC. Epidemiology of endometrial cancer. Best Pract Res Clin Obstet Gynaecol. 2001; 15:341-354
4. Gong TT, Wang YL, Ma XX. Age at menarche and endometrial cancer risk: a dose-response meta-analysis of prospective studies. Sci Rep. 2015; 5:14051
5. Hankinson SE, Danforth KN. Ovarian Cancer. In: Schottenfeld D, Fraumeni J, eds. Cancer epidemiology and prevention, 3rd edn. New York, NY: Oxford University Press, 2006. 1012-1026
6. Wu QJ, Li YY, Tu C, Zhu J, Qian KQ, Feng TB, Li C, Wu L, Ma XX. Parity and endometrial cancer risk: a meta-analysis of epidemiological studies. Sci Rep. 2015; 5:14243
7. Luo J, Chlebowski RT, Hendryx M, Rohan T, Wactawski-Wende J, Thomson CA, Felix AS, Chen C, Barrington W, Coday M, Stefanick M, LeBlanc E, Margolis KL. Intentional Weight Loss and Endometrial Cancer Risk. J Clin Oncol. 2017: O2016705822
8. Modugno F, Ness RB, Chen C, Weiss NS. Inflammation and endometrial cancer: a hypothesis. Cancer Epidemiol Biomarkers Prev. 2005; 14:2840-2847
9. Wallace AE, Gibson DA, Saunders PT, Jabbour HN. Inflammatory events in endometrial adenocarcinoma. J Endocrinol. 2010; 206:141-157
10. Subongkot S, Frame D, Leslie W, Drajer D. Selective cyclooxygenase-2 inhibition: a target in cancer prevention and treatment. Pharmacotherapy. 2003; 23: 9-28
11. Thun MJ, Henley SJ, Patrono C. Nonsteroidal antiinflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002; 94:252-266
12. Gupta RA, DuBois RN. Aspirin, NSAIDS, and colon cancer prevention: mechanisms? Gastroenterology. 1998; 114:1095-1098
13. Shiff SJ, Rigas B. The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs). J Exp Med. 1999; 190:445-450
14. WHO International Agency for Research on Cancer. Phenacetin. In: A review of human carcinogens-part A: pharmaceuticals. Lyon, France: WHO International Agency for Research on Cancer; 2011; 399-422
15. Neill AS, Nagle CM, Protani MM, Obermair A, Spurdle AB, Webb PM. Aspirin, nonsteroidal anti-inflammatory drugs, paracetamol and risk of endometrial cancer: a case-control study, systematic review and meta-analysis. Int J Cancer. 2013; 132:1146-1155
16. Setiawan VW, Matsuno RK, Lurie G, Wilkens LR, Carney ME, Henderson BE, Kolonel LN, Goodman MT. Use of nonsteroidal anti-inflammatory drugs and risk of ovarian and endometrial cancer: the Multiethnic Cohort. Cancer Epidemiol Biomarkers Prev. 2012; 21:1441-1449
17. Walter RB, Brasky TM, White E. Cancer risk associated with long-term use of acetaminophen in the prospective VITamins and lifestyle (VITAL) study. Cancer Epidemiol Biomarkers Prev. 2011; 20:2637-2641
18. Bodelon C, Doherty JA, Chen C, Rossing MA, Weiss NS. Use of nonsteroidal antiinflammatory drugs and risk of endometrial cancer. Am J Epidemiol. 2009; 170:1512-1517
19. Viswanathan AN, Feskanich D, Schernhammer ES, Hankinson SE. Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer. Cancer Res. 2008; 68:2507-2513
20. Moysich KB, Baker JA, Rodabaugh KJ, Villella JA. Regular analgesic use and risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2005; 14:2923-2928
21. Friis S, Nielsen GL, Mellemkjaer L, McLaughlin JK, Thulstrup AM, Blot WJ, Lipworth L, Vilstrup H, Olsen JH. Cancer risk in persons receiving prescriptions for paracetamol: a Danish cohort study. Int J Cancer. 2002; 97:96-101
22. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev. 2004; 56:387-437
23. Ulrich CM, Bigler J, Potter JD. Non-steroidal antiinflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer. 2006; 6:130-140
24. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol. 2012; 9: 259-267
25. Ohno S, Ohno Y, Suzuki N, Inagawa H, Kohchi C, Soma G, Inoue M. Multiple roles of cyclooxygenase-2 in endometrial cancer. Anticancer Res. 2005; 25:3679-3687
26. Kilic G, Gurates B, Garon J, Kang H, Arun B, Lampley CE, Kurzel R, Ashfaq R. Expression of cyclooxygenase-2 in endometrial adenocarcinoma. Eur J Gynaecol Oncol. 2005; 26:271-274
27. Gao J, Niwa K, Sun W, Takemura M, Lian Z, Onogi K, Seishima M, Mori H, Tamaya T. Non-steroidal antiinflammatory drugs inhibit cellular proliferation and upregulate cyclooxygenase-2 protein expression in endometrial cancer cells. Cancer Sci. 2004; 95:901-907
28. Ozalp SS, Eren CY, Bostancioglu RB, Koparal AT. Induction of apoptosis and inhibition of cell proliferation by the cyclooxgenase enzyme blocker nimesulide in the Ishikawa endometrial cancer cell line. Eur J Obstet Gynecol Reprod Biol. 2012; 164:79-84
29. Arango HA, Icely S, Roberts WS, Cavanagh D, Becker JL. Aspirin effects on endometrial cancer cell growth. Obstet Gynecol. 2001; 97:423-427
30. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999; 282:2131-2135
31. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev. 2002; 11:1531-1543
32. Eggen AE. The Tromso Study: frequency and predicting factors of analgesic drug use in a free-living population (12-56 years). J Clin Epidemiol. 1993; 46:1297-1304
33. Antonov KI, Isacson DG. Prescription and nonprescription analgesic use in Sweden. Ann Pharmacother. 1998; 32:485-494
34. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283:2008-2012
35. Wu L, Zhu J. Linear reduction in thyroid cancer risk by oral contraceptive use: a dose-response meta-analysis of prospective cohort studies. Hum Reprod. 2015; 30:2234-2240
36. Yi X, Zhu J, Zhu X, Liu GJ, Wu L. Breastfeeding and thyroid cancer risk in women: A dose-response metaanalysis of epidemiological studies. Clin Nutr. 2016; 35:1039-1046
37. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomized studies in metaanalyses. Available from: http://www.ohri.ca/programs/clinical_epidemiology. (Accessed on 19/March/2017)
38. Gong TT, Wu QJ, Wang YL, Ma XX. Circulating adiponectin, leptin and adiponectin-leptin ratio and endometrial cancer risk: Evidence from a meta-analysis of epidemiologic studies. Int J Cancer. 2015; 137:1967-1978
39. Jiang L, Hou R, Gong TT, Wu QJ. Dietary fat intake and endometrial cancer risk: dose-response meta-analysis of epidemiological studies. Sci Rep. 2015; 5:16693
40. Wu QJ, Gong TT, Wang YZ. Dietary fatty acids intake and endometrial cancer risk: a dose-response meta-analysis of epidemiological studies. Oncotarget. 2015; 6:36081-36097. doi: 10.18632/oncotarget.5555
41. Hamling J, Lee P, Weitkunat R, Ambuhl M. Facilitating meta-analyses by deriving relative effect and precision estimates for alternative comparisons from a set of estimates presented by exposure level or disease category. Stat Med. 2008; 27:954-970
42. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21:1539-1558
43. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50:1088-1101
44. Egger M, Davey SG, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ. 1997; 315: 629-634.